Screening for Advanced Liver Fibrosis Using Non-invasive Tests in Primary Care (ANTICIP-SP)

Grenoble Alpes University Hospital Center (CHU)

Status: Not yet enrolling

Conditions: Hepatic Fibrosis

Study type: Observational

Funder types: Other

Identifiers

NCT06119997

38RC22.0266

Details and patient eligibility

About

Liver fibrosis screening is possible at the asymptomatic stage through a healthcare management strategy currently recommended for patients with risk factors for chronic liver disease. It is based on a sequential strategy involving a 1st-line test, fibrosis score calculation (FIB-4).

Given this opportunity to identify advanced fibrosis in asymptomatic patients, the project aims to set up this screening program in the Grenoble area with Biogroup Laboratories, in collaboration with the Hepato-gastroenterology department (HGE) of Grenoble University Hospital. The aim of this study is to evaluate the success of sequential screening using FIB-4, followed by a specialized fibrosis test for the diagnosis of advanced hepatic fibrosis

Enrollment: 500 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients between 18 and 75 years of age
• FIB-4 2.67
• Patients covered by Health Insurance System

Exclusion criteria

• Prescription triggering FIB-4 emanate from a hepatogastroenterologist or oncologist
• Conditions associated with high risk false-positive FIB-4: ASAT or ALAT > 300 IU/L, platelets <50 G/L or >500 G/L.
• Patient refusing to participate
• Subjects under guardianship or deprived of liberty